- Case report
- Open Access
- Open Peer Review
Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1in a patient with bilateral breast and endometrial adenocarcinoma
© Heitzer et al.; licensee BioMed Central Ltd. 2013
- Received: 12 September 2013
- Accepted: 18 December 2013
- Published: 29 December 2013
Germline genetic testing for familial cancer syndromes is usually performed serially for the most likely genetic causes. In recent years the way genetic testing carried out has changed, as next generation sequencing now allows the simultaneous testing of multiple susceptibility genes at low costs.
Here, we present a female with bilateral breast cancer and endometrial adenocarcinoma. After simultaneous sequencing of 150 genes (890 kb) associated with hereditary cancer we identified pathogenic mutations in two high-penetrance genes, i.e. TP53 and CDH1 that would most likely not have been elucidated by serial screening of candidate genes.
As the two mutated genes are located on different chromosomes and cause different cancer syndromes these findings had a tremendous impact not only on genetic counseling of the index patient and her family but also on subsequent surveillance strategies.
- Multiplex genetic testing
- Cancer susceptibility
- Next generation sequencing
Testing for mutations in high-penetrance cancer predisposition genes, such as BRCA1 or BRCA2, has evolved to an integral part of cancer care because it provides clear information to patients and their families and established guidelines for surveillance with proven benefit exist (http://www.nccn.org). Germline genetic testing is usually performed serially for the most likely genetic causes [1, 2]. As the genetic architecture of cancer predisposition is often complex, genetic testing panels using next-generation sequencing for hereditary cancers have recently been introduced . Here, we present a female with bilateral breast cancer and endometrial adenocarcinoma, where multiplex genetic testing revealed pathogenic mutations in two high-penetrance genes, i.e. TP53 and CDH1. We describe why traditional serial genetic testing would most likely not have elucidated both mutations, which had a tremendous impact on the index patient and her family.
The patient and her family received genetic counseling and written informed consent was obtained. BRCA mutation testing using genomic DNA extracted from peripheral blood leukocytes (PBL) was performed. As no mutation was identified, the index patient was included in a study to evaluate a multiplex genetic testing panel for individuals with cancer.
To this end a total of 150 genes corresponding to 890 kb (Additional file 1: Figure S1), which are associated with hereditary cancer or with frequent somatic mutations according to the COSMIC (http://www.sanger.ac.uk/genetics/CGP/cosmic/) and Cancer Gene Census (http://www.sanger.ac.uk/genetics/CGP/Census/) were enriched using a SeqCap EZ Choice Library (Roche Nimblegen, Madison, WI, USA), following the manufacturer’s instructions. Sequencing was performed on the Roche 454FLX platform using the Lib-L protocol (emPCR Method Manual – Lib-L LV).
For cDNA analyses we transcribed leukocyte derived mRNA into cDNA.
One sister (Figure 1; III-1) of our index patient died at the age of 28 years of breast cancer, diagnosed at 26 years of age, whereas two other siblings (Figure 1; III-2, III-4) were healthy. The mother of our index patient died at the age of 53 years of a myocardial infarction (not shown in the pedigree). On the maternal side there were no cases of known malignant diseases. The family members from the paternal side were all diagnosed and treated in Afghanistan and we were not able to retrieve written documentation. According to the relatives, the father (Figure 1; II-1) died with 63 years of age of gastric cancer. His uncle (Figure 1; I-2) was also diagnosed with gastric cancer at “high age” (>80 years), the son (Figure 1; II-2) of this uncle died of an unknown malignant disease and his two grand-daughters (Figure 1; III-5, III-6) both died at young ages of breast cancer.
The history allowed the differential diagnosis of three autosomal dominantly inherited cancer predisposition syndromes. First, the familial breast-ovarian cancer either due to heterozygous germline mutations in BRCA1 (OMIM #604370) or BRCA2 (OMIM #612555), because the index patient and her sister had early-age-onset (≤50 years) breast cancer and the index patient bilateral disease . Second, Li-Fraumeni syndrome (LFS, OMIM #151623) caused by germline mutations of TP53, which presents with a variety of tumor types, most notably sarcomas, breast cancer, adrenal cortical carcinoma, and brain tumors . Breast cancer is the most common tumor in women with LFS . TP53 genetic testing could have been considered according to the Chompret criteria [7, 8] because both the index patient and one first-degree relative, i.e. her son, had cancers from the LFS tumor spectrum (breast, brain) before 46 years of age. Third, hereditary diffuse gastric cancer (HDGC, OMIM #137215) characterized by diffuse-type gastric cancer and an elevated risk of lobular breast cancer, which is caused by germline mutations of CDH1 coding for E-cadherin . However, the current criteria for CDH1 genetic testing  require histopathological confirmation of diffuse gastric cancer in at least one family member, which we did not have, and both gastric cancer cases were not diagnosed below the age of 50 years.
As families who have a predominance of premenopausal breast cancer are more likely to have mutations in BRCA1 or BRCA2 than in TP53, we started our diagnostic work-up with Sanger sequencing and MLPA (Multiplex Ligation-dependent Probe Amplification) of the two breast cancer genes. However, this did not reveal disease-associated mutations.
We next offered the index patient participation in a study with the aim to evaluate a multiplex genetic testing panel for individuals with cancer. This study was approved by the Ethics Committee of the Medical University of Graz. After extensive counseling and obtaining of a written informed consent, we performed targeted resequencing of 150 genes (890 kb) associated with hereditary cancer or with frequent somatic mutations according to the COSMIC (http://www.sanger.ac.uk/genetics/CGP/cosmic/) and Cancer Gene Census (http://www.sanger.ac.uk/genetics/CGP/Census/) databases. SNV calling identified a total of 446 variants. These variants were filtered first for the non-synonymous, splice acceptor-site and donor-site and insertions/deletions mutation and then against available public databases (dbSNP132, 1000 Genome variants databases). After this variant prioritization we identified heterozygous germline mutations in two high-penetrance genes, i.e. TP53 (c.673-1 G > A) and CDH1 (c.892 G > A, p.A298T), and one mutation in NUP214 (c.2160A > C, p.L720F) which we confirmed by Sanger sequencing (Additional file 2: Table S1). The CDH1 mutation was previously reported in a family with three affected members with diffuse gastric cancer. The mutation dramatically decreases the ability of E-cadherin to mediate cell-cell adhesion and to suppress cell invasion and is therefore listed as causative in HGMD [12, 13]. The TP53 mutation had also been previously observed in a LFS family and analysis of the cDNA had demonstrated that this mutation resulted in a variant transcript . We had only leukocyte derived mRNAs available to confirm this; however, no splice variants were detected in the respective cDNAs. Similar observations with leukocyte derived mRNAs were previously reported for other TP53 splice site mutations  and indicate most likely that the resulting transcripts were unstable and subsequently degraded. As we could not repeat these experiments with an immortalized cell line we carefully analyzed available tumor material from our index patient with immunohistochemistry as outlined below. The NUP214 mutation was not previously reported. To explore the significance of these mutations further, we analyzed them using various prediction programs including SIFT, PolyPhen, and LRT. As expected for the two previously reported pathogenic mutations in CDH1 and TP53 these prediction programs indicated structurally damaging effects. In contrast, these programs suggested for the NUP214 mutation a non-pathogenic effect. Somatic NUP214 mutations were mainly reported in cervix and endometrium carcinoma (http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NUP214#dist), whereas germline NUP214 were to best of our knowledge never reported. Altogether this suggests that the NUP214 mutation does not contribute to the tumor spectrum in our patient.
The lifetime risk of developing cancer is estimated at be as high as 73% for male and 93% for female germline TP53 mutation carriers . While in the past LFS screening programs often lacked effectiveness a recent novel surveillance protocol using non-invasive biochemical and imaging modalities enabled the presymptomatic detection of malignancies in TP53 mutation carriers and prolonged survival . Such a surveillance strategy offers new management options and may change attitudes towards genetic TP53 screening.
Carriers of CDH1 germline mutations have a cumulative gastric cancer risk, before age 75, of 40–67% for men and 63–83% for women and a risk for lobular breast cancer of 39–52% . Total prophylactic gastrectomy is the only reliable intervention for carriers of pathogenic mutations  and was discussed with our patient, illustrating how multiplex genetic testing can change clinical management.
In summary, we demonstrate a case, where multiplex genetic testing enabled us to establish a diagnosis, which would likely have been missed with serial testing. However, the increased risk for detection of variants of unknown significance represents a concern of multiplex genetic panels . An example is the NUP214 mutation, which we observed in the index patient and which very likely did not increase tumor susceptibility. To address this issue we now designed gene panels that only include high penetrance gene with clear implications to hereditary tumor syndromes. The growing awareness about the importance of identifying mutation carriers was recently reflected in recommendations released by the American College of Medical Genetics and Genomics . These guidelines state that anyone whose genome is sequenced for any medical reason should automatically learn -without further consent- about mutations in the cancer-predisposition genes for which risk reducing or live saving measures exist. This proposed shift in handling genetic data and the complexity of hereditary multigene cancer panels as illustrated in this report represent novel challenges for cancer genetics professionals.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Funding was provided by the Förderung durch die Steiermärkische Landesregierung GZ: A3-16.M-94/2009-14.
- Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K: Genetics, genomics, and cancer risk assessment: state of the art and future directions in the Era of personalized medicine. CA Cancer J Clin. 2011, 61: 327-359.PubMedPubMed CentralGoogle Scholar
- Speicher MR, Geigl JB, Tomlinson IP: Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. Lancet Oncol. 2010, 11: 890-898. 10.1016/S1470-2045(09)70359-6.View ArticlePubMedGoogle Scholar
- Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME: Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. J Clin Oncol. 2013, 31: 1267-1270. 10.1200/JCO.2012.46.9403.View ArticlePubMedGoogle Scholar
- Shannon KM, Chittenden A: Genetic testing by cancer site: breast. Cancer J. 2012, 18: 310-319. 10.1097/PPO.0b013e318260946f.View ArticlePubMedGoogle Scholar
- Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF, Savage SA: Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Gene. 2012, 205: 479-487. 10.1016/j.cancergen.2012.06.008.View ArticleGoogle Scholar
- Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63: 6643-6650.PubMedGoogle Scholar
- Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, Bonaiti-Pellie C: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001, 38: 43-47. 10.1136/jmg.38.1.43.View ArticlePubMedPubMed CentralGoogle Scholar
- Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaiti-Pellie C, Stoppa-Lyonnet D, Frebourg T: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009, 27: e108-109. 10.1200/JCO.2009.22.7967. author reply e110View ArticlePubMedGoogle Scholar
- Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F: E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci. 2013, 116: 337-359.View ArticlePubMedGoogle Scholar
- Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C: International gastric cancer linkage C: hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010, 47: 436-444. 10.1136/jmg.2009.074237.View ArticlePubMedPubMed CentralGoogle Scholar
- Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006, 295: 1379-1388. 10.1001/jama.295.12.1379.View ArticlePubMedGoogle Scholar
- Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, et al: Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004, 41: 508-517. 10.1136/jmg.2004.018275.View ArticlePubMedPubMed CentralGoogle Scholar
- Mateus AR, Simoes-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G, Luber B, Seruca R: E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res. 2009, 315: 1393-1402. 10.1016/j.yexcr.2009.02.020.View ArticlePubMedGoogle Scholar
- Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frebourg T: Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet. 2001, 38: 253-257. 10.1136/jmg.38.4.253.View ArticlePubMedPubMed CentralGoogle Scholar
- Verselis SJ, Rheinwald JG, Fraumeni JF, Li FP: Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene. 2000, 19: 4230-4235. 10.1038/sj.onc.1203758.View ArticlePubMedGoogle Scholar
- Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber JE, Syngal S: Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011, 13: 651-657. 10.1097/GIM.0b013e31821628b6.View ArticlePubMedPubMed CentralGoogle Scholar
- Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frebourg T, Lemerle J, Bonaiti-Pellie C, Feunteun J: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000, 82: 1932-1937.View ArticlePubMedPubMed CentralGoogle Scholar
- Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011, 12: 559-567. 10.1016/S1470-2045(11)70119-X.View ArticlePubMedGoogle Scholar
- Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, et al: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007, 297: 2360-2372. 10.1001/jama.297.21.2360.View ArticlePubMedGoogle Scholar
- Couzin-Frankel J: Genome sequencing. Return of unexpected DNA results urged. Science. 2013, 339: 1507-1508. 10.1126/science.339.6127.1507.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/14/129/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.